Fiche publication


Date publication

avril 2022

Journal

Journal of neuro-oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges , Dr SCHOTT Roland


Tous les auteurs :
Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R

Résumé

Immune checkpoint inhibitors (ICIs) can induce adverse neurological effects. Due to its rarity as an adverse effect, meningitis has been poorly described. Therefore, meningitis diagnosis and management can be challenging for specialists. Moreover, meningitis can be an obstacle to resuming immunotherapy. Given the lack of alternatives, the possibility of reintroducing immunotherapy should be discussed on an individual basis. Here, we present a comprehensive systematic review of meningitis related to ICIs.

Mots clés

Aseptic meningitis, Immune-related adverse event, Immunotherapy, Melanoma, Reintroduction

Référence

J Neurooncol. 2022 Apr 13;: